Otros idiomas Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Acciones

TEVA

IL0006290147

Diferido TEL AVIV STOCK EXCHANGE Otros sitios de cotización 14:51:51 06/05/2024			Varia. Cinco días.	Varia. 1 de enero.
5.178 ^ILa	+0,62 %		-1,82 %	+35,67 %

30/04	La FTC impugna los listados de patentes "basura" de Ozempic, Victoza y otros medicamentos	MT
30/04	Las noticias del mediodía: Las acciones de Eli Lilly y HSBC se disparan tras los resultados; BBVA explora una fusión con Sabadell; la FTC impugna 300 listados de patentes "basura	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	03/05
Teva to Present at the 2024 Bank of America Healthcare Conference	03/05
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	02/05
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira	01/05
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor	01/05
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	30/04
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	30/04
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	22/04
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19/04
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19/04
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets	17/04
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	17/04
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	16/04
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

Teva Pharmaceutical Industries Limited : Aún debe relajarse

01 de febrero 2024 a las 11:04

ENTREVISTA - Richard Francis, Consejero Delegado de Teva Pharmaceutical: buen trimestre, aumento de las previsiones anuales

02 de agosto 2023 a las 21:19